Bimzelx® (bimekizumab-bkzx) from UCB is now under FDA review for a total of four potential new indications. Supplemental biologics license applications (sBLA) were submitted in February for three spondyloarthritides indications: psoriatic arthritis (PsA),...
What’s the difference between primary and secondary failure of a biologic? And why does it matter? Exploring an actual patient case, faculty from the DEF Biologic and Small Molecule NP/PA CME Bootcamp—April Armstrong, MD, MPH; David E. Cohen, MD, MPH; Kara Gooding,...
By Joe Gorelick, MSN, FNP-C Psoriatic disease is associated with poor sleep quality and high rates of sleep disturbance, according to the most recent meta-analysis of case-control or cohort studies that assessed sleep quality in individuals with psoriatic disease....
— UPDATE: NDA Approvals for 2023 now stand at 54, with a fourth dermatologic indication approved! Filsuvez® (birch triterpenes) topical gel from Chiesi Global Rare Diseases has received FDA approval for the treatment of partial thickness wounds in patients 6...
Day in and day out, dermatology care professionals face multiple decisions, record pages of medical data, and counsel patients on product selection and use. So what are the best ways to do these various tasks. Dermatology thought leaders share their recommendations in...
In the published studies for biologic treatments for psoriasis, available images account for fewer than one subject per 1,000 participants, a new analysis concludes. More than three-quarters (77%) of studies contain no images at all. Researchers analyzed 152 different...